These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17229505)

  • 21. Understanding orthopoxvirus interference with host immune responses to inform novel vaccine design.
    Pickup DJ
    Expert Rev Vaccines; 2007 Feb; 6(1):87-95. PubMed ID: 17280481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
    Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
    J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
    Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
    Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.
    Hooper JW; Custer DM; Schmaljohn CS; Schmaljohn AL
    Virology; 2000 Jan; 266(2):329-39. PubMed ID: 10639319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections.
    Gilchuk I; Gilchuk P; Sapparapu G; Lampley R; Singh V; Kose N; Blum DL; Hughes LJ; Satheshkumar PS; Townsend MB; Kondas AV; Reed Z; Weiner Z; Olson VA; Hammarlund E; Raue HP; Slifka MK; Slaughter JC; Graham BS; Edwards KM; Eisenberg RJ; Cohen GH; Joyce S; Crowe JE
    Cell; 2016 Oct; 167(3):684-694.e9. PubMed ID: 27768891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two noncompeting human neutralizing antibodies targeting MPXV B6 show protective effects against orthopoxvirus infections.
    Zhao R; Wu L; Sun J; Liu D; Han P; Gao Y; Zhang Y; Xu Y; Qu X; Wang H; Chai Y; Chen Z; Gao GF; Wang Q
    Nat Commun; 2024 May; 15(1):4660. PubMed ID: 38821921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlling orthopoxvirus infections--200 years after Jenner's revolutionary immunization.
    Niemiałtowski MG; Toka FN; Malicka E; Gieryńska ; Spohr de Faundez I; Schollenberger A
    Arch Immunol Ther Exp (Warsz); 1996; 44(5-6):373-8. PubMed ID: 9017154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
    Stittelaar KJ; van Amerongen G; Kondova I; Kuiken T; van Lavieren RF; Pistoor FH; Niesters HG; van Doornum G; van der Zeijst BA; Mateo L; Chaplin PJ; Osterhaus AD
    J Virol; 2005 Jun; 79(12):7845-51. PubMed ID: 15919938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological memory after exposure to variola virus, monkeypox virus, and vaccinia virus.
    Sivapalasingam S; Kennedy JS; Borkowsky W; Valentine F; Zhan MX; Pazoles P; Paolino A; Ennis FA; Steigbigel NH
    J Infect Dis; 2007 Apr; 195(8):1151-9. PubMed ID: 17357051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
    Golden JW; Josleyn MD; Hooper JW
    Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Animal models of orthopoxvirus infection.
    Chapman JL; Nichols DK; Martinez MJ; Raymond JW
    Vet Pathol; 2010 Sep; 47(5):852-70. PubMed ID: 20682806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model.
    Rees DG; Gates AJ; Green M; Eastaugh L; Lukaszewski RA; Griffin KF; Krieg AM; Titball RW
    Antiviral Res; 2005 Feb; 65(2):87-95. PubMed ID: 15708635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-administration of recombinant major envelope proteins (rA27L and rH3L) of buffalopox virus provides enhanced immunogenicity and protective efficacy in animal models.
    Kumar A; Yogisharadhya R; Venkatesan G; Bhanuprakash V; Pandey AB; Shivachandra SB
    Antiviral Res; 2017 May; 141():174-178. PubMed ID: 28259752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice.
    Delaney KN; Phipps JP; Johnson JB; Mizel SB
    Viral Immunol; 2010 Apr; 23(2):201-10. PubMed ID: 20374000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.
    Hooper JW; Thompson E; Wilhelmsen C; Zimmerman M; Ichou MA; Steffen SE; Schmaljohn CS; Schmaljohn AL; Jahrling PB
    J Virol; 2004 May; 78(9):4433-43. PubMed ID: 15078924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and protective efficacy of Semliki forest virus replicon-based DNA vaccines encoding goatpox virus structural proteins.
    Zheng M; Jin N; Liu Q; Huo X; Li Y; Hu B; Ma H; Zhu Z; Cong Y; Li X; Jin M; Zhu G
    Virology; 2009 Aug; 391(1):33-43. PubMed ID: 19559453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques.
    Hatch GJ; Graham VA; Bewley KR; Tree JA; Dennis M; Taylor I; Funnell SG; Bate SR; Steeds K; Tipton T; Bean T; Hudson L; Atkinson DJ; McLuckie G; Charlwood M; Roberts AD; Vipond J
    J Virol; 2013 Jul; 87(14):7805-15. PubMed ID: 23658452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model.
    Chen Z; Earl P; Americo J; Damon I; Smith SK; Yu F; Sebrell A; Emerson S; Cohen G; Eisenberg RJ; Gorshkova I; Schuck P; Satterfield W; Moss B; Purcell R
    J Virol; 2007 Sep; 81(17):8989-95. PubMed ID: 17581986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic effect of two human-like monoclonal antibodies confers protection against orthopoxvirus infection.
    Tamir H; Noy-Porat T; Melamed S; Cherry-Mimran L; Barlev-Gross M; Alcalay R; Yahalom-Ronen Y; Achdout H; Politi B; Erez N; Weiss S; Rosenfeld R; Epstein E; Mazor O; Makdasi E; Paran N; Israely T
    Nat Commun; 2024 Apr; 15(1):3265. PubMed ID: 38627363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene.
    Ibuki K; Funahashi SI; Yamamoto H; Nakamura M; Igarashi T; Miura T; Ido E; Hayami M; Shida H
    J Gen Virol; 1997 Jan; 78 ( Pt 1)():147-52. PubMed ID: 9010298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.